Next Week! CLL Society’s Webinar on Friday, August 14 at 12:30 PM ET 11:30 AM CT / 10:30 AM MT / 9:30 AM PT.
Ever dreamed of coming to a point where your CLL treatment could be paused or stopped, known as limited duration? Will your MRD (minimal or measurable residual disease) status become the new determining indicator of when you can safely stop certain CLL treatments? The good news is that limiting or stopping treatment is a target that researchers are focusing a lot of effort on. Join the CLL Society for our webinar “MRD: What Should it Mean to Me?” as Drs. Anthony Mato & Brian Koffman discuss MRD testing and its growing role in CLL treatment management. Please register here.
ASCO 2020 Dr. Koffman’s “Top 12” Picks Countdown to #3: Dr. Koffman presents a multi-center Phase II study of venetoclax plus dose-adjusted vr-EPOCH for Richters syndrome.
ASH 2019 Dr. Paul Barr on possible “limited duration” venetoclax + Ibrutinib, as well as an explanation as to how MRD testing may correlate better with length of remission than does “response rate” and how it has become increasingly an important indicator regarding how well our treatments are working.
Next Week! What You Need to Know about BTK Inhibitors as Treatment for Your/Your Loved One’s CLL on Monday, August 10 at 11 AM ET
Join this live educational session to hear from a patient and top medical expert about key factors one should consider in selecting the right treatment plan for you or your loved one. The panel will also discuss how to engage with treatment teams in an open dialogue to determine if BTK inhibitor treatment is right for you or your loved one’s CLL. They will also discuss side effect management strategies and how to communicate with your treatment team about them.
We want to hear from you! The panel is already accepting questions and will continue to take your questions during the live session – send them in today!
Interested in learning more? Save the date and register now to join live!
This bears repeating: A reminder that COVID-19 remains a significant threat to our CLL community.Remain vigilant with masks, hand washing and social distancing. Dr. Koffman presents and puts into context, with the help of leading CLL researchers, the latest data published in BLOOD and NATURE on the outcomes of COVID-19 infections in CLL patients. While the results are discouraging, the experts offer a balanced perspective. Click here for Dr. Koffman’s analysis, the experts’ comments, as well as links to the full articles.
Test Before Treat Survey
How much do you know about the critical tests which can predict which patients will do well on or fail certain medications? Prognostic testing should be done before each and every treatment decision; share your experience and test your knowledge by completing the Test Before Treat Survey! At the end of the survey you can request a free Test Before Treat bracelet.
Please Support the CLL Society, the only CLL-specific, physician-curated public charity dedicated to meeting the unmet needs of CLL patients and their caregivers which holds the GuideStar Platinum Seal of Transparency.
The CLL Society is invested in your long life.
Please invest in the long life of the CLL Society by investing in our work.
We are all in this together.
Co-Founder & Communications Director
CLL Society Support Group Meetings Coming Up!
Visit the individual event listings on our website for the most up-to-date information on all CLL Society Support Group meetings.